Weiss Ratings Reiterates “Sell (D-)” Rating for Synaptogenix (NASDAQ:TAOX)

Synaptogenix (NASDAQ:TAOX)‘s stock had its “sell (d-)” rating reiterated by equities researchers at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen cut shares of Synaptogenix from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Synaptogenix presently has a consensus rating of “Sell”.

Synaptogenix Stock Performance

TAOX opened at $7.65 on Wednesday. Synaptogenix has a twelve month low of $1.84 and a twelve month high of $11.98. The stock’s 50-day moving average is $6.62. The firm has a market cap of $26.68 million, a P/E ratio of -0.38 and a beta of 1.89.

Synaptogenix (NASDAQ:TAOX) last released its quarterly earnings results on Friday, August 15th. The company reported ($11.26) earnings per share for the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.